PDF icon PDF herunterladen
Int J Angiol 2022; 31(02): 075-082
DOI: 10.1055/s-0042-1745842
Review Article

Cardiac and Hemodynamic Manifestations of Hereditary Hemorrhagic Telangiectasia

Ahmed Farhan 
1   Division of Interventional Radiology, Russell H. Morgan Department of Radiology and Radiological Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland
,
Muhammad A. Latif
1   Division of Interventional Radiology, Russell H. Morgan Department of Radiology and Radiological Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland
,
Anum Minhas
2   Division of Cardiology, Heart and Vascular Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland
,
Clifford R. Weiss
1   Division of Interventional Radiology, Russell H. Morgan Department of Radiology and Radiological Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland
› Institutsangaben
Funding A.M. and M.A.L. report grant support from the National Institute of Health (NIH). C.R.W. is a consultant for Medtronic, Boston Scientific and Siemens Healthcare and received grant support from Medtronic, Boston Scientific, Siemens Healthcare, Guerbet, and NIH.
› Weitere Informationen
  Lizenzen und Reprints
Preview

Abstract

The autosomal dominant trait hereditary hemorrhagic telangiectasia (HHT) causes multiorgan dysplastic lesions of the vasculature that can activate multiple physiological cascades leading to a broad array of cardiovascular diseases. Up to 78% of patients with HHT develop hepatic arteriovenous malformations (AVMs), which cause a hyperdynamic circulatory state secondary to hepatic/portal shunting. This condition can eventually progress to high-output cardiac failure (HOCF) with continued peripheral tissue hypoxemia. Treatment for HOCF is often limited to supportive measures (diuretics and treatment of anemia); however, recent studies using systemic bevacizumab have shown promise by substantially reducing the cardiac index. In the context of liver AVMs and high cardiac output, the pulmonary vasculature can also experience high flow. Without adequate dilation of pulmonary vessels, post-capillary pulmonary hypertension can develop. Another form of pulmonary hypertension observed in HHT, pulmonary arterial hypertension, is caused by HHT-related mutations in ENG and ACVRL1 causing congestive arteriopathy. Post-capillary pathogenesis is addressed by reducing the high-output state, whereas the pre-capillary state is treated with supportive mechanisms (diuretics, oxygen) and agents targeting pulmonary vasoreactivity: endothelin-1 receptor antagonists and phosphodiesterase-5 inhibitors. If either form of pulmonary hypertension is left untreated or proves refractory and progresses, the common hemodynamic complication is right heart failure. Targeted right heart therapies involve similar strategies to those of pulmonary arterial hypertension, with several experimental approaches under study. In this review, we describe in detail the mechanisms of pathogenesis, diagnosis, and treatment of the hemodynamic complications and associated cardiovascular diseases that may arise in patients with HHT.

Keywords

arteriovenous malformations - high-output cardiac failure - right heart failure - hereditary hemorrhagic telangiectasia - pulmonary hypertension - angiodysplastic lesions - atrial fibrillation


Publikationsverlauf

Artikel online veröffentlicht:
09. Juli 2022

© 2022. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA